Oncogenic signaling of class I PI3K isoforms
Author:
Publisher
Springer Science and Business Media LLC
Subject
Cancer Research,Genetics,Molecular Biology
Link
http://www.nature.com/articles/1210918.pdf
Reference75 articles.
1. Ali K, Bilancio A, Thomas M, Pearce W, Gilfillan AM, Tkaczyk C et al. (2004). Essential role for the p110delta phosphoinositide 3-kinase in the allergic response. Nature 431: 1007–1011.
2. Aoki M, Batista O, Bellacosa A, Tsichlis P, Vogt PK . (1998). The akt kinase: molecular determinants of oncogenicity. Proc Natl Acad Sci USA 95: 14950–14955.
3. Aoki M, Blazek E, Vogt PK . (2001). A role of the kinase mTOR in cellular transformation induced by the oncoproteins P3k and Akt. Proc Natl Acad Sci USA 98: 136–141.
4. Aoki M, Jiang H, Vogt PK . (2004). Proteasomal degradation of the FoxO1 transcriptional regulator in cells transformed by the P3k and Akt oncoproteins. Proc Natl Acad Sci USA 101: 13613–13617.e-pub ahead of print: 1 September 2004.
5. Aoki M, Schetter C, Himly M, Batista O, Chang HW, Vogt PK . (2000). The catalytic subunit of phosphoinositide 3-kinase: requirements for oncogenicity. J Biol Chem 275: 6267–6275.
Cited by 89 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Progress and prospects of biomarker-based targeted therapy and immune checkpoint inhibitors in advanced gastric cancer;Frontiers in Oncology;2024-06-14
2. PI3K/AKT/mTOR Dysregulation and Reprogramming Metabolic Pathways in Renal Cancer: Crosstalk with the VHL/HIF Axis;International Journal of Molecular Sciences;2023-05-07
3. PI 3 Kinase, AKT , and m TOR Inhibitors;Precision Cancer Therapies, Volume 1 ‐ Targeting Oncogenic Drivers and Signaling Pathways in Lymphoid Malignancies;2023-03-15
4. Signaling pathways and therapeutic interventions in gastric cancer;Signal Transduction and Targeted Therapy;2022-10-08
5. The expression and prognostic significance of PIK3CB in lung adenocarcinoma;Annals of Diagnostic Pathology;2022-10
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3